Company Profile

ESTABLISHED IN DECEMBER 1993, MEDICAMEN GROUP HAS VERTICALLY INTEGRATED FACILITIES IN TERMS OF R&D, APIS & FORMULATIONS. THE COMPANY IS NOW FOCUSING ON ONCOLOGY THERAPEUTICS & OTHER GENERICS WITH A VISION TO BE A GLOBAL LEADER IN ONCOLOGY GENERICS BY OFFERING AFFORDABLE MEDICINE WITH BEST-IN-CLASS QUALITY. OUR ONCOLOGY INJECTABLE IS US-FDA APPROVED. WE ALSO RECEIVED ANDA APPROVAL OF BORTEZOMIB INJECTION 3.5MG. THE BHIWADI PLANT APART FROM THE ABOVE, A SET OF 10 NON-ONCOLOGY FORMULATIONS IS ALSO BEING DETERMINED IN R & D FOR EU MARKET FILINGS. THE COMPANY HAS FIRM PLANS & INVESTMENTS FOR GLOBAL ROLLOUT OF ITS ONCOLOGY PRODUCTS IN USA, EUROPE, LATIN AMERICA, ASIA-PACIFIC, MENA ETC. THROUGH A COMBINATION OF OWN TEAM & ALLIANCE PARTNERS.